Key result
Black HFrEF patients have ~100% higher odds of reaching target ACEi/ARB/ARNi doses than White patients.
Why the study?
GDMT improves clinical outcomes in HFrEF, but data on GDMT treatment differences for Black patients are limited.
Does guideline-directed medical therapy use and target dosing differ between Black and White patients with HFrEF?
Population
2825 Black and White patients with HFrEF
Comparison
Black vs White patients
Design
Retrospective health records cohort study
Authors
Loading...
Higher target dosing in Black patients should not yet change practice; leaves open generalizability beyond this integrated system.
Cohort (n=2,825)
Does guideline-directed medical therapy use and target dosing differ between Black and White patients with HFrEF?
Odds Ratio: 2 (95% CI 1.61–2.53)
Absolute Event Rate: 45.2% vs 34.2%
In a large integrated health system, Black patients with HFrEF were more likely to receive certain guideline-directed medical therapies and achieve target doses compared to White patients.
Berry et al. (2026) conducted a cohort in Heart failure with reduced ejection fraction (HFrEF) (n=2,825). Black race vs. White race was evaluated on Treatment to target dose with ACEi/ARB/ARNi among treated patients (OR 2.0, 95% CI 1.61-2.53). Black patients with HFrEF had greater odds of being treated to target with ACEi/ARB/ARNi (OR 2.0; 95% CI 1.61-2.53) and MRAs (OR 1.6; 95% CI 1.01-2.57) compared to White patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: